Skip to main content

Table 4 Clinical biomarkers and sputum differential counts by cohort at Screening/Baseline Visits

From: Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study

Cohorts Healthy Mild Moderate Severe p-value***
n (blood/sputum) 30/20 52/32 55/38 51/40  
FENO (ppb)* NA 32.9 (+64.2/-16.9) 29.1 (+61.0/-13.9) 28.8 (+64.7/-12.9) NA/0.59
bEOS, cells/μl* 112 (+218/-57) 178 (+347/-91) 197 (+435/-89) 210 (+452/-97) 0.0018/0.54
bNEU, 1000 cells/μl* 3.47 (+4.96/-2.42) 3.59 (+4.72/-2.74) 3.64 (+4.92/-2.69) 3.94 (+5.89/-2.63) 0.35/0.32
Serum IgE, RFU* 1.0 (+2.1/-0.7) 8.3 (+25.3/-6.2) 9.8 (+26.7/-7.2) 12.1 (+31.0/-8.7) <0.0001/0.35
Sputum eosinophils, % of WBC* 0.38 (+0.78/-0.25) 1.12 (+5.38/-0.93) 3.12 (+13.62/-2.54) 2.70 (+12.27/-2.21) <0.0001/0.033
Sputum lymphocytes, % of WBC** 1.16 (1.05) 1.29 (1.42) 0.98 (1.19) 0.94 (1.25) 0.64/0.48
Sputum macrophages, % of WBC** 44.57 (19.42) 50.20 (31.17) 32.10 (21.45) 43.04 (26.46) 0.031/0.019
Sputum neutrophils, % of WBC** 53.57 (20.06) 43.88 (30.90) 56.99 (26.13) 48.10 (25.52) 0.19/0.13
  1. *Geometric mean (asymmetric standard deviation) reported by cohort
  2. **Mean (standard deviation) reported by cohort
  3. ***p-value (ANOVA F-test) for differences across severity cohorts, including/excluding healthy control cohort (based on log-transformed data when geometric means reported)
  4. NA = not applicable (not measured in healthy cohort)